Heart rhythm watch: new study tracks ATTR patients on tafamidis
NCT ID NCT06251778
First seen Apr 22, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This study follows 200 adults with a heart condition called ATTR amyloidosis who are taking the drug tafamidis. Researchers will check for dangerous heart rhythm problems every six months using standard tests like electrocardiograms and Holter monitors. The goal is to better understand how often these rhythm issues occur and how much diuretic medication patients need, helping doctors improve care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fondazione IRCCS Policlinico San Matteo
RECRUITINGPavia, 27100, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.